Trial results for a study assessing demographic, pharmacologic, biomarker, and clinical features of participants with Lupus Nephritis were posted on ClinicalTrials.gov on 2026-01-22, involving 193 participants.
Background
Lupus Nephritis is a serious complication of Systemic Lupus Erythematosus (SLE) that affects the kidneys. Understanding the clinical characteristics, demographics, treatment patterns, and health-related quality of life (HRQoL) among patients with Lupus Nephritis is crucial for improving patient care and developing targeted interventions. This multicenter prospective study aimed to provide a comprehensive profile of Lupus Nephritis participants across five Gulf countries, offering valuable regional insights into the disease.
Trial design
This completed study enrolled 193 participants to investigate the clinical characteristics, demographics, treatment, and health-related quality of life (HRQoL) of individuals with Lupus Nephritis, a severe manifestation of Systemic Lupus Erythematosus. The study was a multicenter prospective design conducted across five Gulf countries: United Arab Emirates, Qatar, Bahrain, Kuwait, and Oman.
Key results
The trial reported key measurements related to the number of participants categorized by demographic characteristics for participants with Lupus Nephritis. Specific counts of participants observed include: 143, 50, 88, 3, 30, 58, 9, 4, 1, 8, 6, and 164.
What this means
The posted results offer descriptive data on the demographic characteristics of participants with Lupus Nephritis in the studied Gulf countries. While specific categories for these counts are not detailed in the available data, these measurements contribute to a foundational understanding of the patient population's profile. This information can be valuable for researchers and clinicians seeking to characterize the disease burden and patient demographics in this specific geographic region.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04971590, titled "Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis", were posted on 2026-01-22 on clinicaltrials.gov.